Global Female Infertility Treatment Drugs Market, by Therapy (Gonadotropins, Clomiphene, Letrozole, Metformin, Leuprolide Acetate, Bromocriptine, Estrogens, Ganirelix Acetate, Cetrotide Acetate, and Progesterone), by Route of Administration (Oral and Injectable), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa), is estimated to be valued at US$ 2,649.8 Mn in 2021, and is expected to exhibit a CAGR of 4.1% during the forecast period (2021-2028).
Rising cases of female infertility is expected to drive growth of the global female infertility treatment drugs market during the forecast period. For instance, according to the National Vital Statistics Reports, January 2018, the total fertility rate (TFR) in 2016 was around 1,820.5 births per 1,000 women, which decreased by 1% from 2015, which was around 1,843.5 births per 1,000 women in the U.S. Moreover, according to the Indian Society of Assisted Reproduction (ISAR) report of 2017, infertility affects about 10 to 14% of the Indian population, with higher rates in urban areas, where one out of six couples are affected by it.
Market players are engaged in inorganic activities such as mergers, collaborations, partnerships and acquisitions of companies, which is expected to drive growth of the female infertility treatment drugs market. For instance, in June 2018, Inolife R&D Inc., a life science company, which focuses on needle-free injection technologies, entered into an agreement with Sanzyme Private Limited, an India-based pharmaceutical manufacturer. Under this agreement, Inolife and Sanzyme will work together to identify pharmacokinetic profile and evaluate bio-equivalence of Gonadotropin for pre-filled syringe application, when delivered through needle-free injections.
Global Female Infertility Treatment Drugs Market - Impact of Coronavirus (COVID – 19) Pandemic
COVID-19 outbreak was first reported on December 31, 2019 in Wuhan, China. According to the Coronavirus (COVID-19) Weekly Epidemiological Update by the World Health Organization, over 169 million cases and 3.5 million deaths due to Coronavirus (COVID-19) were reported up till May 30, 2021, across the globe.
The COVID-19 pandemic has affected several markets across the globe and is also expected to hamper demand and supply in global female infertility treatment drugs market. The COVID-19 pandemic has affected the demand and supply of female infertility treatment drugs market in three main ways; by directly affecting the production and demand; by creating disruptions in distribution channels; and by its financial impact on firms and financial markets.
The lockdown imposed in most of the countries has placed an economic burden on the private healthcare sector. Healthcare providers were facing challenges in terms of additional manpower, equipment, consumables, and other resources required to ensure safety in hospitals and to provide treatment to patients with other diseases.
Moreover, the coronavirus pandemic has hampered the development, production, and supply of drugs and other healthcare products, and affected growth of healthcare businesses of various companies across the globe.
Considering the implication of social distancing measure, the footfall in clinics and health institutions has fallen by more than 70% during this pandemic. Owing to this, the adoption of digital health services has increased by three-fold.
Supply chain and manufacturing activities in India, Italy, Spain, U.K., and the U.S. have been disrupted due to the nationwide lockdowns in the past few months, whereas countries such as Saudi Arabia, UAE, Egypt, and others are facing problems with regards to transportation of medical products.
However, healthcare IT industry has witnessed paradigm shift in the adoption of healthcare IT solutions across the ecosystem including drug discovery, drug development, diagnostics, data management, marketing, and patient engagement. Artificial Intelligence, electronic health record (EHR), revenue cycle management, reimbursement data management, and clinical data management solutions are being rapidly adopted by companies, including CROs, insurers, diagnostics, and research institutes for remote data monitoring.
Browse 33 Market Data Tables and 25 Figures spread through 183 Pages and in-depth TOC on Global Female Infertility Treatment Drugs Market, by Therapy (Gonadotropins, Clomiphene, Letrozole, Metformin, Leuprolide Acetate, Bromocriptine, Estrogens, Ganirelix Acetate, Cetrotide Acetate, and Progesterone), by Route of Administration (Oral and Injectable), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, and Asia Pacific, Middle East and Africa)
To know the latest trends and insights prevalent in the Female Infertility Treatment Drugs market, click the link below:
https://www.coherentmarketinsights.com/market-insight/female-infertility-treatment-drugs-market-4475
- Moreover, market strategies such as acquisitions and mergers are expected to propel the market growth of the female infertility treatment drugs. For instance, in August 2020, Bayer announced acquisition of Kandy Therapeutics, a clinical-based company, for US$ 875 million. KaNDy's lead product candidate, NT-814 is a non-hormonal treatment for symptoms of menopause. The drug has completed Phase IIb testing. This acquisition is expected to strengthen Bayer AG’s women healthcare area.
Key Takeaways of the Female Infertility Treatment Drugs Market:
- The global female infertility treatment drugs market is expected to exhibit a CAGR of 4.1% over the forecast period (2021-2028). Europe is expected to be the prominent region for female infertility treatment drugs market over the forecast period due to decrease in female fertility rate. According to Eurostat, in 2019 the fertility rate of females was less than 2% for majority of European countries such as France, Spain, Denmark,etc.
- North America is expected to show growth in the female infertility treatment drugs market over the forecast period (2021-2028), owing to increasing infertility rates in the region. According to the Centers for Disease Control and Prevention, in 2019 around 10% females in the age group of 15-44 years were affected by infertility in U.S. Moreover, according to Fertility Answers report 2020, in U.S. almost 30% of infertility cases are solely due to female infertility.
- Asia Pacific female infertility treatment drugs market is expected to exhibit high growth during the forecast period, owing to an increasing prevalence of infertility rates in the Asian population. For instance, according to the Indian Society of Assisted Reproduction (ISAR) report of 2017, infertility affects around 10 to 14% of the Indian population, with higher rates in urban areas where one out of six couples are affected from it.
- Major players operating in the global female infertility treatment drugs market include Ferring Pharmaceuticals, Merck & Co., Inc., Bayer AG, Abbott Laboratories, Par Pharmaceutical, Inc., Sumitovant, Livzon, Zydus Cadila, Oxolife, and Mankind Pharma.
